Trial Profile

A Phase 2 Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and Pegylated Interferon Alpha (PEG-IFNα) in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elebsiran (Primary) ; Peginterferon alfa (Primary) ; VBI 2601 (Primary)
Indications Hepatitis B
Focus Adverse reactions; Therapeutic Use
Acronyms ENHANCE
Sponsors Brii Biosciences

21 Aug 2026 Results presented in the Brii Biosciences media release.
20 Aug 2026 According to Brii Biosciences media release, detailed data from ENRICH study is expected to be presented at a scientific conference in the second half of 2026.
03 Jul 2026 Results presented in the Brii Biosciences media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com